(Q37077462)

18 August 2017

Racial differences in hepatitis C treatment eligibility (English)

1 reference

18 August 2017

1 reference

20

Mark S Sulkowski

1 reference

18 August 2017

Michael T Melia

1

1 reference

18 August 2017

Andrew J Muir

2

1 reference

18 August 2017

Jonathan McCone

3

1 reference

18 August 2017

Mitchell L Shiffman

4

1 reference

18 August 2017

John W King

5

1 reference

18 August 2017

Steven K Herrine

6

1 reference

18 August 2017

Greg W Galler

7

1 reference

18 August 2017

Joseph R Bloomer

8

1 reference

18 August 2017

Frederick A Nunes

9

1 reference

18 August 2017

Kimberly A Brown

10

1 reference

18 August 2017

Kevin D Mullen

11

1 reference

18 August 2017

Natarajan Ravendhran

12

1 reference

18 August 2017

Reem H Ghalib

13

1 reference

18 August 2017

Navdeep Boparai

14

1 reference

18 August 2017

Ruiyun Jiang

15

1 reference

18 August 2017

Stephanie Noviello

16

1 reference

18 August 2017

Clifford A Brass

17

1 reference

18 August 2017

Janice K Albrecht

18

1 reference

18 August 2017

John G McHutchison

19

1 reference

18 August 2017

IDEAL Study Team

21

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

18 August 2017

1 reference

18 August 2017

54

1 reference

18 August 2017

1

1 reference

18 August 2017

70-78

1 reference

Diabetes care in black and white veterans in the southeastern U.S.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Diagnosis, management, and treatment of hepatitis C: an update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

United States Renal Data System 2008 Annual Data Report

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Rate and predictors of treatment prescription for hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

American Gastroenterological Association technical review on the management of hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Race differences in long-term diabetes management in an HMO.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Barriers to diabetes education in urban patients: perceptions, patterns, and associated factors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Hepatitis C in African Americans: summary of a workshop

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Comparison of uninsured and privately insured hospital patients. Condition on admission, resource use, and outcome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3736356

A National Study of Chronic Disease Prevalence and Access to Care in Uninsured U.S. Adults

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FHEP.24358

Peripheral blood count abnormalities among patients with hepatitis C in the United States

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21488082

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Participation in cancer clinical trials: race-, sex-, and age-based disparities

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21488082

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/HEP.24358

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

21488082

1 reference